SCHEMBL24673243

SCHEMBL24673243

CCC(C)OCC(=O)NCCCCCCCCCCCNC(=O)C(C)CC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.43
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CASP2 P42575 1/20 0.38
ALDH1A1 P00352 2/20 0.37
ALDH1A2 O94788 1/20 0.37
ALDH2 P05091 1/20 0.37
ALDH1A3 P47895 1/20 0.37
MMP8 P22894 1/20 0.36
NAAA Q02083 1/20 0.36
BRD4 O60885 3/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EPHX1 P07099 2/20 0.35
RRM1 P23921 1/20 0.35
EPHX2 P34913 1/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25654169 0.92 EPHX2 (0.39) FAAHMEN1KMT2AALDH1A1EPHX2
SCHEMBL24029656 0.89 FAAH (0.44) FAAHMEN1KMT2ACASP2ALDH1A1
SCHEMBL23568385 0.84 FAAH (0.38) FAAHMEN1KMT2AALDH1A1BRD4
SCHEMBL23560051 0.84 KMT2A (0.40) FAAHMEN1KMT2ACASP2ALDH1A1
SCHEMBL25697264 0.82 EPHX2 (0.43) FAAHMEN1KMT2AEPHX2TSHR
SCHEMBL22861649 0.82 EPHX2 (0.40) FAAHMEN1KMT2AALDH1A1EPHX2
SCHEMBL24765423 0.82 EPHX2 (0.40) FAAHMEN1KMT2AALDH1A1EPHX2
SCHEMBL24508251 0.82 EPHX2 (0.43) FAAHMEN1KMT2AEPHX2TSHR
SCHEMBL17527573 0.82 ALDH1A2 (0.52) MEN1KMT2AALDH1A1ALDH1A2ALDH2
SCHEMBL17853878 0.80 USP2 (0.50) MEN1KMT2AALDH1A1ALDH1A2ALDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FAAH 1771/4885MEN1 4055/4885KMT2A 445/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FAAH 1771/4885MEN1 4055/4885KMT2A 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.